(Q40709933)

23 September 2017

title

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. (English)

1 reference

23 September 2017

1 reference

Agata Klejman

1

1 reference

23 September 2017

Lori Rushen

2

1 reference

23 September 2017

Andrea Morrione

3

1 reference

23 September 2017

Artur Slupianek

4

1 reference

23 September 2017

Tomasz Skorski

5

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

23 September 2017

1 reference

23 September 2017

volume

21

1 reference

23 September 2017

issue

38

1 reference

23 September 2017

page(s)

5868-5876

1 reference

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Structure and function of phosphatidylinositol 3-kinase: a potential second messenger system involved in growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Cell biology of CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Signalling via phosphoinositide 3OH kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Role of Ras/ERK-dependent pathway in the erythroid differentiation of K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Activation of Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Differential effects of phosphatidylinositol 3-kinase inhibition on intracellular signals regulating GLUT4 translocation and glucose transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Signalling through the lipid products of phosphoinositide-3-OH kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibi

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Signal transduction by wild-type and leukemogenic Abl proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Therapy of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205724

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1205724

1 reference

Dimensions Publication ID

23 September 2017

1029394417

0 references

1 reference